These data suggest that the administration of ld-IL-2 to patients with T1D led to changes in the phenotype and distribution of GZMB+ NK cells over time, likely a consequence of changes in expansion and trafficking in these patients. This evidence concerns the gene GZMB and type 1 diabetes mellitus.